Companies / AFP

AFT PHARMACEUTICALS LIMITED

ASX:AFPPharmaceuticals, Biotechnology & Life Sciences
104.9M shares on issueASX (delayed) · as of 28 July 2026$3.57price · delayed$393.3Mmarket cap · indicative
A
Dilution grade

No issuance filings since 2024; no dilution pressure signals in current disclosures

Cash runwayno data — not a quarterly (4C/5B) cash filer
Share-count growth (24m)0.0%no issuance filings since 2024
Raise cadence (24m)0 cash raises
Options & rights overhang0.6% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

AFT PHARMACEUTICALS LIMITED had 105M ordinary shares on issue as of June 2026. The company has not raised capital in the past 24 months (zero raises recorded in the period) and has lodged no new share-issuance Appendix 2A filings since January 2024. Options and rights could convert into 651,000 new shares, equal to 0.6% of the current share count, with 0% of current shares in the money. The company does not lodge a current quarterly cash report, so no quarterly cash balance or funding-runway figure is on record. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.6%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · not a quarterly filer

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 104.9M per ASX (delayed) (28 July 2026).
104.868M104.870M104.873MDec 24Sept 25July 26

Cash runway

Not a quarterly cash filer. This company does not lodge Appendix 4C/5B quarterly cash reports, so cash runway does not apply.

Issuance timeline

Latest 1 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
21 June 20262A · quoted issueAFP : ORDINARY FULLY PAID FOREIGN EXEMPT NZX104.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.6%
Total overhang · of current shares
0.0%
In the money · at current price
651k
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026AFT R&D portfolio offers multi-$bn dollar market potential
27 July 2026AFT R&D portfolio offers multi-$bn market potential
23 July 2026Pitt St Research initiates coverage on AFT Pharmaceuticals
20 July 2026Scomara Tentative Approval by US FDA
6 July 2026AFT reports ongoing sales growth and R&D progress
2 July 2026Notice of Annual Meeting of Shareholders 2026
24 June 2026Update - Dividend/Distribution - AFP
23 June 2026FDA allows AFT injectable iron project clinical study
23 June 2026FDA allows AFT injectable iron project clinical study
21 June 2026Application for quotation of securities - AFP
21 June 2026Capital Change Notice
25 May 2026Update - Dividend/Distribution - AFP
24 May 2026Annual Meeting and Closing Date for Director Nominations
22 May 2026Dividend/Distribution - AFP
21 May 2026Issue of unlisted options
21 May 2026$PDividend distribution update
20 May 2026$PFY26 NZX App2
20 May 2026$PFY26 Annual Report
20 May 2026$PFY26 results presentation
20 May 2026$PFY26 results

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.